Antibody to the polysaccharide capsule of type III group B streptococci (GBS) and complement are essential to host defense against systemic infection in neonates. Interactions between C3 degradation products and specific neutrophil receptors mediate the attachment and ingestion of these organisms. To evaluate the influence of capsule on C3 disposition, we compared the C3 fragments released from a highly encapsulated clinical isolate (M861) with those from an unencapsulated mutant Group B streptococci (GBS) are a common cause of serious infection in neonates and young infants (1). Agespecific susceptibility to infection with GBS is ascribed both to virulence factors of the organism and to immaturity of host defense mechanisms in infancy (3, 4). Opsonization by complement is an essential prelude to efficient phagocytosis of these organisms. As has been documented by a number of investigators, type-specific antibody also is required for maximal opsonization and phagocytosis of type III GBS (2, 7, 24) .
Group B streptococci (GBS) are a common cause of serious infection in neonates and young infants (1) . Agespecific susceptibility to infection with GBS is ascribed both to virulence factors of the organism and to immaturity of host defense mechanisms in infancy (3, 4) . Opsonization by complement is an essential prelude to efficient phagocytosis of these organisms. As has been documented by a number of investigators, type-specific antibody also is required for maximal opsonization and phagocytosis of type III GBS (2, 7, 24) .
The third component of complement, C3, is the convergence point for the alternative and classical complement pathways. Binding of degradation products of C3 to bacterial surface structures facilitates recognition by specific neutrophil receptors that mediate the attachment and ingestion of organisms. Located on the surface of neutrophils are CR1 (CD35) receptors, which bind the opsonically active C3 cleavage fragment C3b in preference to its further-degraded products iC3b and C3d. Neutrophils also possess CR3 (CD11b) receptors, which have ligand specificity limited to iC3b. Compared with those from adults, neutrophils from neonates are deficient in CR3 expression after stimulation (6, 27) . Recently, Smith et al. (26) demonstrated that in the setting of a low level of anticapsular antibody, blockade of either CR1 or CR3 receptors by using monoclonal or polyclonal antibodies significantly impaired the opsonophagocytosis of type III GBS. However, CR3 blockade had the more profound influence. These investigators hypothesized that deposition of specific C3 cleavage fragments upon the GBS surface is an important ligand-receptor interaction in host defense against GBS and that iC3b might be the predominant C3 fragment bound. Three observations indicate that the capsular polysaccha-* Corresponding author.
ride of type III GBS is a major virulence factor. First, strains of type III GBS that cause invasive infection elaborate greater quantities of capsule than do strains that are associated with asymptomatic colonization (21, 25) . Second, a sufficient amount of antibody directed against the type III capsular polysaccharide promotes opsonophagocytosis in vitro (7), protects against lethal challenge in experimental models (5, 11) , and correlates with protection against invasive disease in the newborn (3, 4) . Finally, transposon mutants of isogenic strains of type III GBS defective in production of the type III polysaccharide capsule (23) or expressing an asialo capsular polysaccharide (29) are relatively avirulent in experimental models of infection (23, 29) . The present experiments were designed to examine the effect of the capsular polysaccharide of type III GBS on patterns of C3 derivative deposition. Since sialylation of the type III GBS surface may inhibit activation of the alternative complement pathway (9, 10), the mutant strain expressing an asialo capsular polysaccharide was used to examine sialylation as a determinant of C3 deposition. Finally, the effect of antibody specific for the capsular polysaccharide in augmenting C3 deposition or degradation on the encapsulated strain was delineated.
MATERIALS AND METHODS
Bacterial strains and growth. A type III GBS strain, M861, originally recovered from the cerebrospinal fluid of an infant with purulent meningitis, was used as a representative clinical isolate. Strain COH 31-15, derived by transposon mutagenesis of strain COH 31r/s, is a mutant type III GBS strain that lacks capsular polysaccharide (23 Opsonization and experimental procedure. GBS were opsonized in a volume of 600 ,ul comprising 150 RId of the bacterial suspension (-2 x 108 CFU/ml) and 450 RI of serum diluted in Dulbecco's phosphate-buffered saline to give a final serum concentration of 30%. Opsonization was carried out at 37°C with gentle agitation, either in a shaking water bath or in a Thermomixer (model 5436, Eppendorf). After opsonization for 1 to 90 min, the reaction was stopped by cooling the suspension to 4°C on ice. Vials were centrifuged at 13,000 x g (model 235B, Fisher), and the pellets were washed with phosphate-buffered saline-1% sodium dodecyl sulfate (SDS) (BioRad, Richmond, Calif.) to remove noncovalently bound C3 (18) . The pellet was suspended in 1 M hydroxylamine (Sigma, St. Louis, Mo.)-1% SDS (pH 9.0 in NaHCO3-NaCO3) to disrupt ester bonds between the complement fragments and the bacterial surface (13, 14, (18) (19) (20) . Centrifugation (13,000 x g) was used to separate the bacterial pellet from the C3 fragment suspension. Two hundred microliters of the C3 fragment suspension was reduced with 10 mM dithiothreitol (Sigma)-1% SDS at 37°C for 60 min and then alkylated with 22 mM iodoacetamide (Sigma) at 37°C for 60 min (13, 14) . Fragments then were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) or were frozen at -70°C until use (17) . 5, respectively) . The presence of the 105-kDa chain indicates C3b. The 67-and 40-kDa chains indicate iC3b. The 75-kDa chain is the beta chain common to both C3b and iC3b. Preparations of C3 and C3b and further degradation products of C3 are shown in lanes 7 and 8, respectively. Lane 6 is blank.
were diluted 1:2 in sample buffer and subjected to SDS-PAGE with a 7.5% polyacrylamide gel under reducing conditions (17) . After electrophoresis (175 mV, 35 min) of the samples in a mini-PROTEAN II apparatus (BioRad), the gel was equilibrated in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol). Proteins were transferred electrophoretically to nitrocellulose paper (100 mV) for 1 h in a Mini-Transblot apparatus (BioRad). After blocking nonspecific binding sites with phosphate-buffered saline-1% bovine serum albumin overnight, the nitrocellulose paper was incubated in a 1:250 dilution of goat anti-human C3 (Jackson ImmunoResearch, West Grove, Pa.) for 2 h. The blot was washed several times in Tris-0.05% bovine serum albumin and then incubated with alkaline phosphatase-conjugated rabbit anti-goat IgG (1:500 dilution) (Cappel, West Chester, Pa.). The blot was developed by using bromochloroindolyl phosphate-Nitro Blue Tetrazolium (Calbiochem, La Jolla, Calif.) for 2 min. The reaction was stopped with PBS phosphate-buffered saline-20 mM EDTA (Sigma), and the blot was dried.
Two C3 preparations were used as controls. One contained intact C3 alpha chain (115 kDa) and C3b, consisting of an alpha chain of 105 kDa and a beta chain of 75 kDa (13, 14) ; the other preparation, a control prepared by David Gordon (Flinders Medical Center, South Australia), contained further degradation products of C3, including the intact beta chain (75 kDa) common to both C3b and iC3b, a 40-kDa alpha subunit component of iC3b, a 33-kDa band representing C3d, and several smaller degradation subunits.
RESULTS
Standardization of the assay. Preliminary experiments were performed with S. pneumoniae type 3 to confirm the technical adequacy of the method of C3 fragment generation and detection. In the analysis of C3 fragments covalently bound to S. pneumoniae, Hostetter (13) opsonization (lane 5), C3b, iC3b, and C3d were present. However, after 30 min of opsonization or longer, iC3b alone was detectable, as shown by the 75-kDa beta chain and the 67-and 40-kDa alpha subunits. These results corroborated those reported by Hostetter (13) and therefore confirmed the accuracy of our method.
Experiments using dilutions of sera at final concentrations ranging from 1 to 38% were performed to determine the optimal serum concentration for detection of C3 fragments. At serum concentrations exceeding 23% in the final reaction mixture, C3 fragments released from the surface of type III GBS were readily detectable. A 30% serum concentration in the final reaction volume was selected for use in subsequent experiments. This concentration minimized the volume of hypogammaglobulinemic serum required and has been used routinely in our laboratory in assays of opsonophagocytosis of GBS (7).
C3 fragments from type III GBS. Having standardized the experimental conditions, we evaluated C3 fragments released from the surface of the highly encapsulated type III GBS strain M861. Figure 2 is a Western blot of C3 fragments released after opsonization of this strain for 5 to 90 min with hypogammaglobulinemic serum. Both C3b and iC3b were detectable at all opsonization times. As the duration of opsonization increased, the bands representing iC3b and C3b intensified. By using the same experimental conditions, the unencapsulated mutant (COH 31-15) was evaluated. The C3 fragments detected after opsonization for 5 to 90 min were similar to those observed for the encapsulated isolate (Fig. 3) . Both C3b and iC3b were present, suggesting that C3 deposition and degradation can occur on type III GBS in the absence of the polysaccharide capsule. In contrast to the pattern observed with the encapsulated strain, increasing the duration of opsonization did not alter the intensity of C3b or iC3b bands. The pattern of C3 fragments released from the surface of the mutant strain expressing an asialo capsular polysaccharide (COH 31-21) was similar to that of the unencapsulated strain, COH 31-15 (Fig. 4) (Fig. 5) . At both bacterial concentrations, C3 fragments were detected after 5 min of opsonization. C3 fragments released from the same strain opsonized with serum containing specific antibody were detected by Western blotting (Fig. 6 ). When compared with the Western blot for hypogammaglobulinemic serum (Fig. 5) , the most striking difference was seen at the lower concentration of GBS, 107 CFU/ml. When op- sonized with serum containing specific antibody, both C3b and iC3b were easily detectable after 1 min (Fig. 6 ). This suggested that the presence of antibody enhanced C3 fragment deposition and degradation during the early phases of opsonization. Qualitatively, the presence of antibody was associated with release of C3 fragments earlier in opsonization (illustrated in Fig. 5 and 6 , lanes 8).
DISCUSSION
As has been shown with several bacterial pathogens (12, 13, 15, 16) , the C3 cleavage fragments on bacterial surfaces influence ligand-receptor interactions. Differences in the C3 fragments deposited have been noted among serotypes of S. pneumoniae (13) . Serotypes commonly causing infection in childhood, such as 6A and 14, bear primarily iC3b on their surfaces, while serotypes less virulent for children bear C3b preferentially. Relating this finding to GBS, it is possible that the age-limited susceptibility to infection with type III GBS is a consequence of deficient neutrophil complement receptor expression (6, 27) 4 , 5, and 6, respectively) or 107 CFU/ml (lanes 8, 9, and 10, respectively). Lanes 1 and 2 contain C3 degradation controls, and lanes 3 and 7 are blank. designed to evaluate the effect of capsular polysaccharide upon deposition and degradation of ester-bound C3 fragments on type III GBS. Given that the polysaccharide capsule is a major structure contributing to the virulence of GBS, comparative experiments were performed by using a highly encapsulated strain and transposon mutants either without a capsule or with a capsular polysaccharide lacking terminal sialic acid residues. The correlation between type III GBS-specific antibody and protection from invasive infection due to this GBS serotype and its essential role in human host defense has been described thoroughly (2-4, 7,  24) . Thus, we also evaluated the influence of human antibody to type III GBS capsular polysaccharide on the deposition and degradation of C3 fragments.
We first evaluated the C3 fragments covalently bound by ester linkages to the surface of an encapsulated strain of type III GBS. Examined in the setting of undetectable specific antibody to capsular polysaccharide, C3 deposition and degradation occurred; both C3b and iC3b were readily detected. As the duration of opsonization increased, the bands of iC3b, as well as C3b, intensified. Since degradation of surface-bound C3b to iC3b is mediated by factor I and requires a bacterial surface that permits binding of the essential coenzyme H (22) , the presence of detectable iC3b suggested that the encapsulated type III GBS was a receptive surface. The pattern of intensification of all C3 fragment bands with increasing duration of opsonization was observed only with the encapsulated strain. The availability of an unencapsulated mutant (COH 31-15) that failed to express type III GBS capsular polysaccharide provided a unique opportunity for our comparison of the C3 fragments covalently bound by ester bonds. Although both C3b and iC3b were present, there was not a progression of intensity of the C3 fragment bands with increasing duration of opsonization. This suggests that C3 deposition and degradation can occur in the absence of the polysaccharide capsule but that encapsulation permits progressive deposition of C3 fragments with increasing duration of opsonization.
Sialic acid, the terminal moiety on the side chain of the repeating backbone of the type III GBS polysaccharide capsule (28) , is an important determinant of virulence (21, 25) and a potent inhibitor of alternative pathway activation (9) . In addition, the absence of sialic acid on certain bacterial surfaces has been associated with a lower-affinity binding of H for fixed C3b (22) . By studying a type III GBS mutant that elaborates an asialo capsule (COH 31-21), we were able to evaluate the influence of the sialic acid moiety on C3 fragment deposition and degradation. These experiments were conducted without selective blockade of the classical complement pathway. Both C3b and iC3b were detected, suggesting that, when deposition is promoted by either complement pathway, degradation of C3b to iC3b does occur. The pattern of C3 fragments was similar to that of the unencapsulated mutant. Although the asialo mutant contains an epitope that is serologically cross-reactive with S. pneumoniae, type 14 (29) , its C3 degradation pattern differed from that described for type 14 pneumococci. Hostetter (13) found that iC3b was present but that C3b and C3d were absent after 20 and 90 min of opsonization. In our analysis of C3 fragments bound to the asialo mutant, both C3b and iC3b were present throughout 90 min of opsonization. This difference suggests that although the polysaccharides of the asialo mutant of type III GBS and S. pneumoniae, type 14, are antigenically identical, other exposed structures may influence C3 deposition and degradation. By comparing the C3 fragment patterns from these three strains, we concluded In addition to complement, antibody directed against the capsular polysaccharide is essential in host defense against type III GBS. To determine the influence of antibody on C3 deposition, we analyzed and compared C3 fragments released from GBS opsonized with sera that contained or lacked antibody with specificity for the type III GBS polysaccharide. In both settings, C3b and iC3b were detected. However, in the presence of a moderate concentration of specific antibody, C3 fragments were detectable very early in opsonization and the bands representing these fragments were intensified. This suggested that C3 deposition on type III GBS is facilitated by the presence of antibody. The mechanisms by which specific antibody enhances deposition of C3 fragments have not been defined but could involve alteration of surface moieties to provide a protected docking site on the bacterial surface.
In conclusion, we evaluated the C3 fragments bound by ester bonds to three strains of opsonized type III GBS. Both C3b and iC3b were detectable on unencapsulated and desialylated mutant strains of type III GBS. Although both C3b and iC3b were present on the encapsulated and fully sialylated strain following opsonization, the intensity of fragments detected noticeably increased with increasing duration of opsonization of this strain. Thus, capsular polysaccharide influences the binding of C3 fragments and may influence the ligand-receptor interactions of opsonized GBS. This surface, bearing both C3b and iC3b, may contribute to the virulence of encapsulated strains of type III GBS among neonates lacking specific antibody if receptors for these ligands are deficient among neonatal neutrophils. Type-specific antibody, the other crucial component of host defense against GBS, facilitates C3 fragment deposition and degradation. If antibody enhances deposition of this important opsonin and promotes interaction with Fc receptors in neonatal neutrophils, then methods of providing passive immunity to susceptible neonates should be investigated further.
